Ambroxol as a Treatment for Parkinson's Disease Dementia
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The present study will test the hypothesis that the medication Ambroxol is safe and well
tolerated and will improve cognitive and motor symptoms of Parkinson's Disease Dementia
(PDD). Ambroxol has been shown to raise the levels of the enzyme beta-glucocerebrosidase
resulting in lower the levels of the protein alpha-synuclein, both of which have been shown
to improve cognition in mouse models. This will be a 52 week trial of Ambroxol in 75
individuals with PDD. Participants will undergo clinical, neuropsychological and neuroimaging
assessment throughout the study to assess changes.
Phase:
Phase 2
Details
Lead Sponsor:
Lawson Health Research Institute
Collaborators:
London Health Sciences Centre University of Western Ontario, Canada Weston Brain Institute Weston Foundation